Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Observational Study on Predictors of Response to Invirase (Saquinavir) Treatment in Treatment-naïve Patients With HIV Infection
- Conditions
- HIV Infections
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 151
- Registration Number
- NCT01297127
A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT01296971
A Study of the Correlation Between Pharmacokinetic and Pharmacodynamic Parameters of CellCept (Mycophenolate Mofetil).
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT01292226
A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 240
- Registration Number
- NCT01292603
- Locations
- 🇧🇷
Hospital das Clinicas - FMUSP, Sao Paulo, SP, Brazil
🇦🇷HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto Oncología, Córdoba, Argentina
🇩🇪Klinik der Uni zu Köln; Klinik für Innere Medizin, Köln, Germany
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4
- Registration Number
- NCT01290718
A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 41
- Registration Number
- NCT01290094
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1418
- Registration Number
- NCT01287741
- Locations
- 🇨🇦
Humber River Hospital, Toronto, Ontario, Canada
🇺🇸UCLA - School of Medicine; Division of Hematology/Oncology, Los Angeles, California, United States
🇵🇱Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii, Gdansk, Poland
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT01287754
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 51
- Registration Number
- NCT01286753
Safety Extension Study of TRO19622 in ALS
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 271
- Registration Number
- NCT01285583
- Locations
- 🇫🇷
CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement, Lille, France
🇫🇷HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel, Bron Cedex, France
🇫🇷Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac, Montpellier, France